SARA MARTIN: Open Payments
NPI 1073975983 · OWENSBORO, KY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$983 in 50 payments from 15 companies in 2025. Trend: 2023 $919 · 2024 $1,239 · 2025 $983
Food & beverage: $983
| Company | Payments | Amount |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $196 |
| Novartis Pharmaceuticals Corporation | 7 | $174 |
| GlaxoSmithKline, LLC. | 7 | $118 |
| Amgen Inc. | 4 | $86 |
| GENZYME CORPORATION | 4 | $84 |
| Genentech USA, Inc. | 3 | $66 |
| Regeneron Healthcare Solutions, Inc. | 2 | $57 |
| CSL Behring | 2 | $46 |
| Lilly USA, LLC | 2 | $37 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $28 |
Products named: DUPIXENT, HYQVIA, Rhapsido, TEZSPIRE, NUCALA, Xolair, CUVITRU, Hizentra.
Industry payments across KY — which companies pay providers there.
